We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is BioVie (BIVI) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has BioVie Inc. (BIVI - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
BioVie Inc. is a member of our Medical group, which includes 1187 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. BioVie Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for BIVI's full-year earnings has moved 0.8% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that BIVI has returned about 0.2% since the start of the calendar year. At the same time, Medical stocks have lost an average of 18.1%. This means that BioVie Inc. is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is Immunovant, Inc. (IMVT - Free Report) . The stock has returned 41% year-to-date.
In Immunovant, Inc.'s case, the consensus EPS estimate for the current year increased 2.6% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, BioVie Inc. is a member of the Medical - Drugs industry, which includes 218 individual companies and currently sits at #95 in the Zacks Industry Rank. On average, stocks in this group have lost 32.5% this year, meaning that BIVI is performing better in terms of year-to-date returns.
On the other hand, Immunovant, Inc. belongs to the Medical - Biomedical and Genetics industry. This 562-stock industry is currently ranked #67. The industry has moved -19% year to date.
BioVie Inc. and Immunovant, Inc. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is BioVie (BIVI) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has BioVie Inc. (BIVI - Free Report) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
BioVie Inc. is a member of our Medical group, which includes 1187 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. BioVie Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for BIVI's full-year earnings has moved 0.8% higher within the past quarter. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that BIVI has returned about 0.2% since the start of the calendar year. At the same time, Medical stocks have lost an average of 18.1%. This means that BioVie Inc. is outperforming the sector as a whole this year.
Another Medical stock, which has outperformed the sector so far this year, is Immunovant, Inc. (IMVT - Free Report) . The stock has returned 41% year-to-date.
In Immunovant, Inc.'s case, the consensus EPS estimate for the current year increased 2.6% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, BioVie Inc. is a member of the Medical - Drugs industry, which includes 218 individual companies and currently sits at #95 in the Zacks Industry Rank. On average, stocks in this group have lost 32.5% this year, meaning that BIVI is performing better in terms of year-to-date returns.
On the other hand, Immunovant, Inc. belongs to the Medical - Biomedical and Genetics industry. This 562-stock industry is currently ranked #67. The industry has moved -19% year to date.
BioVie Inc. and Immunovant, Inc. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.